RxDoctor Payments Data

Krysten Perque

Family · Thibodaux, LANPI 1992048011

Payments from drug & device makers

$2,509in general payments, 2019–2025

Across 109 payments — averaging $23.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Esperion Therapeutics, Inc.$1K
  • AbbVie$300
  • Medtronic$172
  • Takeda Pharmaceuticals U.S.A., Inc.$150
  • Novo Nordisk$134
  • Pfizer$102
  • plus $380 from 12 others

What the payments were for

  • Food & beverage$2,509100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,509 in reported general payments places this provider in the 80th percentile of 3,610 family providers in Louisiana.

See all family providers in Louisiana

Medicare billing

Part B allowed, 2024
$19,933
Medicare patients
72
Services billed
261

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide28$36,731
OzempicSemaglutide13$25,965
Ezetimibe68$1,513
Np ThyroidThyroid,pork28$1,336
Armour ThyroidThyroid,pork19$1,153
Rosuvastatin Calcium53$772
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine27$750
Liothyronine Sodium20$689
Levothyroxine Sodium81$523
Bupropion XlBupropion Hcl22$390
Celecoxib25$344
Valsartan15$264
Metoprolol Succinate47$258
Escitalopram Oxalate17$251
Nifedipine ErNifedipine23$221

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$134$25,96513 claims
AbbVieArmour Thyroid$300$1,15319 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,610 family providers in Louisiana.

Other family in Thibodaux

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →